{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:18Z","timestamp":1790758638503,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01669-2","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:08:21Z","timestamp":1790755701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling Framework for Economic Evaluation of Disease-Modifying Therapies in Parkinson\u2019s Disease: Evidence Review and Expert Opinion"],"prefix":"10.1007","author":[{"given":"Anshul","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifuddin","family":"Kharawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Asis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kotzeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"Suppl. 1","key":"1669_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(Suppl. 1):S3-8. https:\/\/doi.org\/10.3233\/JPD-181474.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1669_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland JC, Williams-Gray CH, Barker RA. Barker, The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur J Neurosci. 2019;49(3):328\u201338. https:\/\/doi.org\/10.1111\/ejn.14094.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"1669_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"1669_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107190","volume":"130","author":"KE Anderson","year":"2025","unstructured":"Anderson KE, Marras C, Amara A, Chahine LM, Eberly S, Hosamath A, et al. What Parkinson\u2019s disease patients say in their own words about their mood and anxiety symptoms. Parkinsonism Relat Disord. 2025;130:107190. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107190.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1669_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cns.13549","volume":"27","author":"N Zhao","year":"2021","unstructured":"Zhao N, Yang Y, Zhang L, Zhang Q, Balbuena L, Ungvari GS, et al. Quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis of comparative studies. CNS Neurosci Ther. 2021;27(3):270\u20139. https:\/\/doi.org\/10.1111\/cns.13549.","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"1669_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.parkreldis.2013.06.015","volume":"19","author":"O Oguh","year":"2013","unstructured":"Oguh O, Kwasny M, Carter J, Stell B, Simuni T. Caregiver strain in Parkinson\u2019s disease: National Parkinson Foundation Quality Initiative study. Parkinsonism Relat Disord. 2013;19(11):975\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.06.015.","journal-title":"Parkinsonism Relat Disord"},{"key":"1669_CR7","doi-asserted-by":"publisher","unstructured":"Welter L, Kruse C, Montes-Martinez M, et al. The costs of Parkinson\u2019s disease in Europe: results of the costs of illness in neurology initiative. 2026. https:\/\/doi.org\/10.1002\/mds.70491","DOI":"10.1002\/mds.70491"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson\u2019s disease in the US. NPJ Parkinsons Dis. 2020;6:15. https:\/\/doi.org\/10.1038\/s41531-020-0117-1.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"1669_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/08919887231195219","volume":"37","author":"WW Aamodt","year":"2024","unstructured":"Aamodt WW, Kluger BM, Mirham M, Job A, Lettenberger SE, Mosley PE, et al. Caregiver burden in Parkinson disease: a scoping review of the literature from 2017\u20132022. J Geriatr Psychiatry Neurol. 2024;37(2):96\u2013113. https:\/\/doi.org\/10.1177\/08919887231195219.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1669_CR10","unstructured":"The Lewin Group Inc. Economic burden of Parkinson\u2019s disease and atypical parkinsonism in the United States. 2026. https:\/\/www.michaeljfox.org. Accessed 3 Aug 2026."},{"issue":"10","key":"1669_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/s2468-2667(26)00010-1","volume":"41","author":"J Dams","year":"2023","unstructured":"Dams J, Zapp JJ, K\u00f6nig HH. Modelling the cost effectiveness of treatments for Parkinson\u2019s disease: an updated methodological review. Pharmacoeconomics. 2023;41(10):1205\u201328. https:\/\/doi.org\/10.1016\/s2468-2667(26)00010-1.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1669_CR12","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2468-2667(26)00010-1","volume":"11","author":"A Lastuka","year":"2026","unstructured":"Lastuka A, Mitchell AJ, Cogswell IE, Dalos J, Tsakalos G, Oros A, et al. Estimating the costs of informal care for individuals with brain health disorders from 2000 to 2021: a modelling study. Lancet Public Health. 2026;11(3):e176\u201386. https:\/\/doi.org\/10.1016\/S2468-2667(26)00010-1.","journal-title":"Lancet Public Health."},{"issue":"12","key":"1669_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol. 2024;20(12):695\u2013707. https:\/\/doi.org\/10.1038\/s41582-024-01034-x.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1669_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"ME Freitas","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson\u2019s disease. Semin Neurol. 2017;37(2):147\u201357. https:\/\/doi.org\/10.1055\/s-0037-1602423.","journal-title":"Semin Neurol"},{"issue":"4","key":"1669_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u201331. https:\/\/doi.org\/10.1038\/nrneurol.2017.27.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1669_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029740","volume":"9","author":"CB Carroll","year":"2019","unstructured":"Carroll CB, Webb D, Stevens KN, Vickery J, Eyre V, Ball S, et al. Simvastatin as a neuroprotective treatment for Parkinson\u2019s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study. BMJ Open. 2019;9(10):e029740. https:\/\/doi.org\/10.1136\/bmjopen-2019-029740.","journal-title":"BMJ Open"},{"issue":"12","key":"1669_CR17","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024;30(12):3669\u201375. https:\/\/doi.org\/10.1038\/s41591-024-03270-6.","journal-title":"Nat Med"},{"issue":"5","key":"1669_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993","volume":"11","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: the \u2018Exenatide-PD3\u2019 study. BMJ Open. 2021;11(5):e047993. https:\/\/doi.org\/10.1136\/bmjopen-2020-047993.","journal-title":"BMJ Open"},{"issue":"15","key":"1669_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"issue":"5","key":"1669_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342. https:\/\/doi.org\/10.1212\/WNL.17.5.427.","journal-title":"Neurology"},{"key":"1669_CR21","unstructured":"ClinicalTrials.gov. Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson\u2019s disease (Exenatide-PD3) (NCT04232969). 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04232969. Accessed 3 Aug 2026."},{"issue":"6","key":"1669_CR22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3233\/JPD-230446","volume":"14","author":"B Ribba","year":"2024","unstructured":"Ribba B, Simuni T, Marek K, Siderowf A, Diack C, Pierrillas PB, et al. Modeling of Parkinson\u2019s disease progression and implications for detection of disease modification in treatment trials. J Parkinsons Dis. 2024;14(6):1225\u201335. https:\/\/doi.org\/10.3233\/JPD-230446.","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"1669_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.parkreldis.2006.04.006","volume":"12","author":"J Hjelmgren","year":"2006","unstructured":"Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U, et al. Estimating the value of novel interventions for Parkinson\u2019s disease: an early decision-making model with application to dopamine cell replacement. Parkinsonism Relat Disord. 2006;12(7):443\u201352. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.04.006.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1669_CR24","doi-asserted-by":"publisher","first-page":"1922163","DOI":"10.1080\/20016689.2021.1922163","volume":"9","author":"C Chandler","year":"2021","unstructured":"Chandler C, Folse H, Gal P, Chavan A, Proskorovsky I, Franco-Villalobos C, et al. Modeling long-term health and economic implications of new treatment strategies for Parkinson\u2019s disease: an individual patient simulation study. J Mark Access Health Policy. 2021;9(1):1922163. https:\/\/doi.org\/10.1080\/20016689.2021.1922163.","journal-title":"J Mark Access Health Policy."},{"issue":"6","key":"1669_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/mds.25407","volume":"28","author":"J Dams","year":"2013","unstructured":"Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson\u2019s disease. Mov Disord. 2013;28(6):763\u201371. https:\/\/doi.org\/10.1002\/mds.25407.","journal-title":"Mov Disord"},{"issue":"8","key":"1669_CR26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/mds.26740","volume":"31","author":"J Dams","year":"2016","unstructured":"Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WMM, Krack P, et al. Cost-effectiveness of neurostimulation in Parkinson\u2019s disease with early motor complications. Mov Disord. 2016;31(8):1183\u201391. https:\/\/doi.org\/10.1002\/mds.26740.","journal-title":"Mov Disord"},{"issue":"10","key":"1669_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747\u201359. https:\/\/doi.org\/10.1007\/s00125-004-1527-z.","journal-title":"Diabetologia"},{"issue":"4","key":"1669_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0272989X16662009","volume":"37","author":"M Tabberer","year":"2017","unstructured":"Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van M\u00f6lken MPMH, Chambers M, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Mak. 2017;37(4):440\u201352. https:\/\/doi.org\/10.1177\/0272989X16662009.","journal-title":"Med Decis Mak"},{"issue":"11","key":"1669_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40273-025-01532-w","volume":"43","author":"CG Fawsitt","year":"2025","unstructured":"Fawsitt CG, Gallagher E, Singh A, Baker H, Kayongo E, Thom H, et al. Developing a comprehensive framework for cost-effectiveness evaluation in metastatic castration-sensitive prostate cancer: insights from a systematic review. Pharmacoeconomics. 2025;43(11):1323\u201333. https:\/\/doi.org\/10.1007\/s40273-025-01532-w.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1669_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","volume":"15","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health. 2012;15(6):804\u201311. https:\/\/doi.org\/10.1016\/j.jval.2012.06.016.","journal-title":"Value Health"},{"issue":"5","key":"1669_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989x12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Mak. 2012;32(5):667\u201377. https:\/\/doi.org\/10.1177\/0272989x12454577.","journal-title":"Med Decis Mak"},{"key":"1669_CR32","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"1669_CR33","unstructured":"Siebert U, M\u00fchlberger N, Behrend C, Wasem J. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung okonomischer Evaluationsstudien in Deutschland. In: Leidl R, von der Schulenburg JM, Wasem J, editors. Ans\u00e4tze und Methoden der \u00f6konomischen Evaluation: eine internationale Perspektive. Hannover: HTA-Berichte; 1999."},{"key":"1669_CR34","unstructured":"Kaltenthaler E, Tappenden P, Paisley S, Squires H. Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models. In: NICE DSU Technical Support Document 13. National Institute for Health and Clinical Excellence (NICE). 2011. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/full-list. Accessed 3 Aug 2026."},{"issue":"6","key":"1669_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15(6):843\u201350. https:\/\/doi.org\/10.1016\/j.jval.2012.04.012.","journal-title":"Value Health"},{"key":"1669_CR36","unstructured":"Davis S, Stevenson M, Tappenden P, Wailoo A. Cost-effectiveness modelling using patient-level simulation. In: NICE DSU Technical Support Document 15. National Institute for Health and Care Excellence (NICE). 2014. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/full-list. Accessed 3 Aug 2026."},{"issue":"1","key":"1669_CR37","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/13696998.2025.2560759","volume":"27","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Bergmann L, Belsey J, Boodhna T, Leoncini E. Foslevodopa\/foscarbidopa (LDp\/CDp) in advanced Parkinson\u2019s disease (aPD): demonstration of savings from a societal perspective in the UK. J Med Econ. 2024;27(1):1267\u201378. https:\/\/doi.org\/10.1080\/13696998.2025.2560759.","journal-title":"J Med Econ"},{"issue":"4","key":"1669_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1227\/neu.0000000000002274","volume":"92","author":"X Guo","year":"2023","unstructured":"Guo X, Feng C, Pu J, Jiang H, Zhu Z, Zheng Z, et al. Deep brain stimulation for advanced Parkinson disease in developing countries: a cost-effectiveness study from China. Neurosurgery. 2023;92(4):812\u20139. https:\/\/doi.org\/10.1227\/neu.0000000000002274.","journal-title":"Neurosurgery"},{"issue":"9","key":"1669_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.clinthera.2024.06.016","volume":"46","author":"N Kwak","year":"2024","unstructured":"Kwak N, Lee MJ, Kang HY, Lee H. Cost-effectiveness Analysis of COMT-inhibitors as adjuvant treatments to levodopa in patients with advanced Parkinson\u2019s disease. Clin Ther. 2024;46(9):670\u20136. https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.016.","journal-title":"Clin Ther"},{"issue":"3","key":"1669_CR40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40120-025-00730-0","volume":"14","author":"D Nyholm","year":"2025","unstructured":"Nyholm D, Eggington S, Holm A. Therapies for advanced Parkinson\u2019s disease in Sweden: a cost-effectiveness analysis using real-world data. Neurol Ther. 2025;14(3):801\u201312. https:\/\/doi.org\/10.1007\/s40120-025-00730-0.","journal-title":"Neurol Ther."},{"issue":"12","key":"1669_CR41","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/mds.29624","volume":"38","author":"R Pahwa","year":"2023","unstructured":"Pahwa R, Merola A, Soileau M, Alobaidi A, Pickard AS, Kandukuri PL, et al. Cost-effectiveness of carbidopa-levodopa enteral suspension for advanced Parkinson\u2019s disease in the United States. Mov Disord. 2023;38(12):2308\u201312. https:\/\/doi.org\/10.1002\/mds.29624.","journal-title":"Mov Disord"},{"key":"1669_CR42","unstructured":"National Institute for Health and Care Excellence (NICE). Foslevodopa-foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms. Committee Papers and Public Meeting Slides. 2023. London: NICE; 2023. https:\/\/www.nice.org.uk\/guidance\/ta934\/evidence. Accessed 30 Jul 2026."},{"key":"1669_CR43","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Foslevodopa-Foscarbidopa (Vyalev): CADTH Reimbursement Recommendation.Ottawa (ON): CADTH. 2023. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR. Accessed 30 Jul 2026."},{"key":"1669_CR44","unstructured":"Scottish Medicines Consortium (SMC). Levodopa 20mg\/mL + carbidopa monohydrate 5mg\/mL + entacapone 20mg\/mL intestinal gel (Lecigon\u00ae). Glasgow: SMC; 2024. https:\/\/scottishmedicines.org.uk\/medicines. Accessed 30 Jul 2026."},{"issue":"11","key":"1669_CR45","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2165\/11538520-000000000-00000","volume":"30","author":"H Groenendaal","year":"2010","unstructured":"Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson\u2019s disease in the United States: a cost-utility model. Clin Drug Investig. 2010;30(11):789\u201398. https:\/\/doi.org\/10.2165\/11538520-000000000-00000.","journal-title":"Clin Drug Investig"},{"key":"1669_CR46","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/j.wneu.2020.02.150","volume":"138","author":"JCY Fann","year":"2020","unstructured":"Fann JCY, Chang KC, Yen AMF, Chen SLS, Chiu SYH, Chen HHC, et al. Cost-effectiveness analysis of deep brain stimulation for Parkinson disease in Taiwan. World Neurosurg. 2020;138:e459\u201368. https:\/\/doi.org\/10.1016\/j.wneu.2020.02.150.","journal-title":"World Neurosurg."},{"issue":"7","key":"1669_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/ner.12474","volume":"19","author":"JB Pietzsch","year":"2016","unstructured":"Pietzsch JB, Garner AM, Marks WJ Jr. Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States. Neuromodulation. 2016;19(7):689\u201397. https:\/\/doi.org\/10.1111\/ner.12474.","journal-title":"Neuromodulation"},{"issue":"2","key":"1669_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3111\/13696998.2014.979937","volume":"18","author":"E Walter","year":"2015","unstructured":"Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson\u2019s disease in the UK and Germany. J Med Econ. 2015;18(2):155\u201365. https:\/\/doi.org\/10.3111\/13696998.2014.979937.","journal-title":"J Med Econ"},{"issue":"1","key":"1669_CR49","first-page":"23","volume":"9","author":"RJG Arnold","year":"2017","unstructured":"Arnold RJG, Layton A, Rustay NR, Chen S. Cost-effectiveness of extended-release carbidopa-levodopa for advanced Parkinson\u2019s disease. Am J Pharm Benefits. 2017;9(1):23\u20139.","journal-title":"Am J Pharm Benefits."},{"issue":"5","key":"1669_CR50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40273-022-01132-y","volume":"40","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, et al. The cost effectiveness of levodopa-carbidopa intestinal gel in the treatment of advanced Parkinson\u2019s disease in England. Pharmacoeconomics. 2022;40(5):559\u201374. https:\/\/doi.org\/10.1007\/s40273-022-01132-y.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1669_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13696998.2018.1553179","volume":"22","author":"S Kalabina","year":"2019","unstructured":"Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales. J Med Econ. 2019;22(3):215\u201325. https:\/\/doi.org\/10.1080\/13696998.2018.1553179.","journal-title":"J Med Econ"},{"issue":"5","key":"1669_CR52","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3111\/13696998.2011.598201","volume":"14","author":"J Lowin","year":"2011","unstructured":"Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK. J Med Econ. 2011;14(5):584\u201393. https:\/\/doi.org\/10.3111\/13696998.2011.598201.","journal-title":"J Med Econ"},{"issue":"11","key":"1669_CR53","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/13696998.2017.1379411","volume":"20","author":"J Lowin","year":"2017","unstructured":"Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, et al. The cost-effectiveness of levodopa\/carbidopa intestinal gel compared to standard care in advanced Parkinson\u2019s disease. J Med Econ. 2017;20(11):1207\u201315.","journal-title":"J Med Econ"},{"key":"1669_CR54","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH Common Drug Review: pharmacoeconomic review report: apomorphine (Movapo): indication: the acute, intermittent treatment of hypomobility \u201coff\u201d episodes (\u201cend-of-dose wearing off\u201d and unpredictable \u201con\/off\u201d episodes) in patients with advanced Parkinson\u2019s disease. Ottawa (ON): CADTH; 2018. https:\/\/www.cadth.ca\/Movapo_PE_Report.pdf. Accessed 30 Jul 2026."},{"issue":"2","key":"1669_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36469\/jheor.2021.29488","volume":"8","author":"A Thach","year":"2021","unstructured":"Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR. Cost-effectiveness of apomorphine sublingual film as an \u201con-demand\u201d treatment for \u201cOFF\u201d episodes in patients with Parkinson\u2019s disease. J Health Econ Outcomes Res. 2021;8(2):82\u201392. https:\/\/doi.org\/10.36469\/jheor.2021.29488.","journal-title":"J Health Econ Outcomes Res."},{"issue":"3","key":"1669_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40266-013-0150-4","volume":"31","author":"JFM van Boven","year":"2014","unstructured":"van Boven JFM, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. Economic evaluation of ropinirole prolonged release for treatment of Parkinson\u2019s disease in the Netherlands. Drugs Aging. 2014;31(3):193\u2013201. https:\/\/doi.org\/10.1007\/s40266-013-0150-4.","journal-title":"Drugs Aging"},{"issue":"7","key":"1669_CR57","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3233\/JPD-223247","volume":"12","author":"CVM Verschuur","year":"2022","unstructured":"Verschuur CVM, Suwijn SR, de Haan RJ, Boel JA, Post B, Bloem BR, et al. Cost-effectiveness and cost-utility of early levodopa in Parkinson\u2019s disease. J Parkinsons Dis. 2022;12(7):2171\u20138. https:\/\/doi.org\/10.3233\/JPD-223247.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1669_CR58","first-page":"99","volume":"4","author":"RA Farkouh","year":"2012","unstructured":"Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits. 2012;4(3):99\u2013107.","journal-title":"Am J Pharm Benefits."},{"issue":"7","key":"1669_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159340","volume":"11","author":"PR Eldridge","year":"2016","unstructured":"Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep brain stimulation for Parkinson\u2019s disease with early motor complications: a UK cost-effectiveness analysis. PLoS\u00a0One. 2016;11(7):e0159340. https:\/\/doi.org\/10.1371\/journal.pone.0159340.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"1669_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3171\/2020.5.JNS20692","volume":"135","author":"Y Meng","year":"2021","unstructured":"Meng Y, Pople CB, Kalia SK, Kalia LV, Davidson B, Bigioni L, et al. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson\u2019s disease. J Neurosurg. 2021;135(1):273\u20138. https:\/\/doi.org\/10.3171\/2020.5.JNS20692.","journal-title":"J Neurosurg"},{"issue":"2","key":"1669_CR61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00228-022-03438-4","volume":"79","author":"NGM Oonk","year":"2023","unstructured":"Oonk NGM, Dorresteijn LDA, van den Berg AD, van der Palen J, Movig KLL, Nijmeijer HW, et al. Cost-utility analysis of a structured medication review compared to usual care in Parkinson\u2019s disease. Eur J Clin Pharmacol. 2023;79(2):289\u201397. https:\/\/doi.org\/10.1007\/s00228-022-03438-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1669_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/13696998.2021.1916750","volume":"24","author":"RN Hansen","year":"2021","unstructured":"Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson\u2019s disease patients treated with levodopa\/carbidopa. J Med Econ. 2021;24(1):563\u20139. https:\/\/doi.org\/10.1080\/13696998.2021.1916750.","journal-title":"J Med Econ"},{"issue":"1","key":"1669_CR63","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","volume":"261","author":"S Eggington","year":"2014","unstructured":"Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease. J Neurol. 2014;261(1):106\u201316. https:\/\/doi.org\/10.1007\/s00415-013-7148-z.","journal-title":"J Neurol"},{"key":"1669_CR64","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.wneu.2015.11.062","volume":"89","author":"Y Kawamoto","year":"2016","unstructured":"Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-effectiveness analysis of deep brain stimulation in patients with Parkinson\u2019s disease in Japan. World Neurosurg. 2016;89:628-35.e1. https:\/\/doi.org\/10.1016\/j.wneu.2015.11.062.","journal-title":"World Neurosurg."},{"issue":"1","key":"1669_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-025-00907-2","volume":"11","author":"JR Mammen","year":"2025","unstructured":"Mammen JR, Adams JL, Mangrum R, Xiao Y, Barbosa W, Tyo M, et al. Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson\u2019s disease. NPJ Parkinsons Dis. 2025;11(1):65. https:\/\/doi.org\/10.1038\/s41531-025-00907-2.","journal-title":"NPJ Parkinsons Dis."},{"issue":"9996","key":"1669_CR66","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3.","journal-title":"Lancet"},{"issue":"5","key":"1669_CR67","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/brainsci15050467","volume":"15","author":"RM Hendricks","year":"2025","unstructured":"Hendricks RM, Biswas S. Cluster analysis of motor symptoms in early-diagnosed Parkinson\u2019s disease patients. Brain Sci. 2025;15(5):467. https:\/\/doi.org\/10.3390\/brainsci15050467.","journal-title":"Brain Sci"},{"key":"1669_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.977985","volume":"14","author":"K Dou","year":"2022","unstructured":"Dou K, Ma J, Zhang X, Shi W, Tao M, Xie A. Multi-predictor modeling for predicting early Parkinson\u2019s disease and non-motor symptoms progression. Front Aging Neurosci. 2022;14:977985. https:\/\/doi.org\/10.3389\/fnagi.2022.977985.","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"1669_CR69","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mdc3.14321","volume":"12","author":"A Lerner","year":"2025","unstructured":"Lerner A, Mammen JR, Tyo M, Auinger P, Al-Rubayie R, Xiao Y, et al. Fox insight: most bothersome symptoms in early-stage Parkinson\u2019s disease. Mov Disord Clin Pract. 2025;12(4):510\u20135. https:\/\/doi.org\/10.1002\/mdc3.14321.","journal-title":"Mov Disord Clin Pract."},{"issue":"4","key":"1669_CR70","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JPD-225068","volume":"13","author":"JR Mammen","year":"2023","unstructured":"Mammen JR, Speck RM, Stebbins GT, M\u00fcller MLTM, Yang PT, Campbell M, et al. Relative meaningfulness and impacts of symptoms in people with early-stage Parkinson\u2019s disease. J Parkinsons Dis. 2023;13(4):619\u201332. https:\/\/doi.org\/10.3233\/JPD-225068.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"1669_CR71","doi-asserted-by":"publisher","first-page":"21171","DOI":"10.1038\/s41598-024-71555-4","volume":"14","author":"JR Mammen","year":"2024","unstructured":"Mammen JR, Tyo M, Cadorette J, Adams JL, Xiao Y, Stephenson D, et al. Understanding what aspects of Parkinson\u2019s disease matter most to patients and families. Sci Rep. 2024;14(1):21171. https:\/\/doi.org\/10.1038\/s41598-024-71555-4.","journal-title":"Sci Rep"},{"issue":"2","key":"1669_CR72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2125.2012.04192.x","volume":"74","author":"TC Vu","year":"2012","unstructured":"Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of Parkinson\u2019s disease and their response to treatment. Br J Clin Pharmacol. 2012;74(2):267\u201383. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04192.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1669_CR73","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/mds.70303","volume":"41","author":"AD Macleod","year":"2026","unstructured":"Macleod AD, McLernon DJ, Camacho M, et al. Prognosis in Parkinson\u2019s disease: an individual patient data meta-analysis of six European incidence cohorts. Mov Disord. 2026;41(7):1798\u2013811. https:\/\/doi.org\/10.1002\/mds.70303.","journal-title":"Mov Disord"},{"key":"1669_CR74","doi-asserted-by":"publisher","first-page":"108390","DOI":"10.1016\/j.parkreldis.2026.108390","volume":"149","author":"Y Li","year":"2026","unstructured":"Li Y, McLernon DJ, Lawson RA, et al. Personalised prediction of institutionalisation in Parkinson\u2019s: prognostic factor identification and model development and validation using IPD meta-analysis. Parkinsonism Relat Disord. 2026;149:108390. https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108390.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1669_CR75","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/0272989X12455463","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Mak. 2012;15(6):812\u201320. https:\/\/doi.org\/10.1177\/0272989X12455463.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1669_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/0272989X12455462","volume":"15","author":"J Karnon","year":"2012","unstructured":"Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, M\u00f6ller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Mak. 2012;15(6):821\u20137. https:\/\/doi.org\/10.1177\/0272989X12455462.","journal-title":"Med Decis Mak"},{"key":"1669_CR77","unstructured":"Institute for Clinical and Economic Review (ICER). Tavapadon for Parkinson\u2019s disease: draft background and scope. 2026. https:\/\/icer.org\/wp-content\/-Scope_For-Publication_030926.pdf. Accessed 13 Sept 2026."},{"key":"1669_CR78","unstructured":"European Medicines Agency (EMA). Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson\u2019s disease. 2025. https:\/\/www.ema.europa.eu.pdf. Accessed 30 Jul 2026."},{"key":"1669_CR79","unstructured":"Parkinson\u2019s Progression Markers Initiative (PPMI). Parkinson\u2019s progression markers initiative. https:\/\/www.ppmi-info.org\/. Accessed 3 Aug 2026."},{"key":"1669_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105928","volume":"118","author":"Y Li","year":"2024","unstructured":"Li Y, McLernon DJ, Counsell CE, Macleod AD. Incidence and risk factors of institutionalisation in Parkinson\u2019s disease and atypical parkinsonism. Parkinsonism Relat Disord. 2024;118:105928. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105928.","journal-title":"Parkinsonism Relat Disord"},{"key":"1669_CR81","unstructured":"World Health Organization. (2001). International classification of functioning, disability and health: ICF. World Health Organization. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/83e1c3e0-cf9e-4063-a424-71ccc9a84ded\/content. Accessed 3 Aug 2026."},{"key":"1669_CR82","unstructured":"Lin G, Whittington MD, Pearson SD, Rind DM, Ollendorf DA, Tice JA, et al. Beta-amyloid antibodies for early Alzheimer\u2019s disease: effectiveness and value; evidence report. Institute for Clinical and Economic Review (ICER); 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/04\/ICER_Alzheimers-Disease_Final-Report_For-Publication_04172023.pdf. Accessed 13 Sept 2026."},{"issue":"4","key":"1669_CR83","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/13696998.2020.1796360","volume":"4","author":"H Cranmer","year":"2020","unstructured":"Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Pharmacoecon Open. 2020;4(4):663\u201375. https:\/\/doi.org\/10.1080\/13696998.2020.1796360.","journal-title":"Pharmacoecon Open"},{"issue":"12","key":"1669_CR84","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1617\u201325. https:\/\/doi.org\/10.1016\/j.jval.2020.08.2094.","journal-title":"Value Health."},{"issue":"2","key":"1669_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1467-9876.2009.00684.x","volume":"59","author":"CH Jackson","year":"2010","unstructured":"Jackson CH, Sharples LD, Thompson SG. Structural and parameter uncertainty in Bayesian cost-effectiveness models. J R Stat Soc Ser C Appl Stat. 2010;59(2):233\u201353. https:\/\/doi.org\/10.1111\/j.1467-9876.2009.00684.x.","journal-title":"J R Stat Soc Ser C Appl Stat"},{"issue":"6","key":"1669_CR86","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835\u201342. https:\/\/doi.org\/10.1016\/j.jval.2012.04.014.","journal-title":"Value Health."},{"issue":"2","key":"1669_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1669_CR88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Siderowf A, Postuma RB, Berg D, Adler CH, Bloem BR, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1669_CR89","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"issue":"12","key":"1669_CR90","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.27802","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov Disord. 2015;30(12):1600\u201311. https:\/\/doi.org\/10.1002\/mds.27802.","journal-title":"Mov Disord"},{"issue":"12","key":"1669_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077766","volume":"13","author":"G Ymeri","year":"2023","unstructured":"Ymeri G, Salvi D, Olsson CM, Wassenburg MV, Tsanas A, Svenningsson P. Quantifying Parkinson\u2019s disease severity using mobile wearable devices and machine learning: the ParkApp pilot study protocol. BMJ Open. 2023;13(12):e077766. https:\/\/doi.org\/10.1136\/bmjopen-2023-077766.","journal-title":"BMJ Open"},{"key":"1669_CR92","unstructured":"Michael J. Fox Foundation. VALUE-PD: dynamic microsimulation of Parkinson\u2019s disease: evaluating lifecourse impacts of disease modifying therapies. https:\/\/www.michaeljfox.org\/grant\/dynamic-microsimulation-parkinsons-disease-evaluating-lifecourse-impacts-disease-modifying. Accessed 3 Aug 2026."},{"issue":"11","key":"1669_CR93","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/mdc3.70165","volume":"12","author":"A Wijers","year":"2025","unstructured":"Wijers A, Evers SMAA, Tissingh G, van Mastrigt GAPG. A bottom-up analysis of the cost of illness of Parkinson\u2019s disease in the Netherlands from a societal perspective. Mov Disord Clin Pract. 2025;12(11):1849\u201358. https:\/\/doi.org\/10.1002\/mdc3.70165.","journal-title":"Mov Disord Clin Pract."},{"issue":"3","key":"1669_CR94","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4103\/aian.AIAN_239_17","volume":"20","author":"S Pandey","year":"2017","unstructured":"Pandey S, Srivanitchapoom P. Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management. Ann Indian Acad Neurol. 2017;20(3):190\u20138. https:\/\/doi.org\/10.4103\/aian.AIAN_239_17.","journal-title":"Ann Indian Acad Neurol"},{"key":"1669_CR95","unstructured":"National Institute for Health and Care Excellence (NICE). NICE technology appraisal and highly specialised technologies guidance: the manual. NICE process and methods. Reference number: PMG36. https:\/\/www.nice.org.uk\/process\/pmg36. Accessed 3 Aug 2026."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01669-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:08:29Z","timestamp":1790755709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01669-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":95,"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01669-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anshul Shah and Saifuddin Kharawala are employees of Red Nucleus, Inc., who were contracted by F. Hoffmann-La Roche to conduct this research. Anna Kotzeva, Matthew May, and Gennaro Pagano are employees and shareholders of F. Hoffmann-La Roche. Katharina Klapper is an independent consultant under contract with The Michael J. Fox Foundation for Parkinson\u2019s Research and acted on its behalf in the conduct of this work. The author has no other competing interests. Angelica Asis was an employee of Parkinson Canada at the time of preparation of this article and acted on its behalf in the conduct of this work. The author has no other competing interests. Richard Dodel has participated in industry-sponsored research projects from Lilly, Roche; served as a consultant for Lilly, Roche, Eisai, and Novo Nordisk; received honoraria for scientific presentations from AbbVie, Bayer Vital, Lilly, Eisai, Schwabe, and Roche; received publication royalties from Kohlhammer, Elsevier, and Thieme; and is an inventor on patents from Philipps University Marburg for immunization in neurodegenerative diseases. Camille Carroll receives a salary from Newcastle University and Parkinson\u2019s UK. She has received advisory, consulting, or lecture fees from AbbVie, Astex Pharmaceuticals, Bial, Britannia, inMuneBio, Mission Therapeutics, Merz, and Roche, and research funding from Parkinson\u2019s UK, Edmond J Safra Foundation, John Black Charitable Foundation, Gatsby Charitable Foundation, van Andel Institute, Michael J Fox Foundation, National Institute of Health and Care Research, and Cure Parkinson\u2019s. Per Odin has performed lectures at and\/or been an advisor with honorarium for AbbVie, Bial, Britannia, Convatec, Global Kinetics, Insightec, Lundbeck, Merz, Navamedic, Nordic Infucare, Roche, Stada, UCB, and Zambon. Per Odin has participated as an investigator in clinical studies performed by AbbVie, Bial, Global Kinetics, IRL, Merz, Navamedic, Orion Pharma, UCB, and Zambon. Per Odin has received research grants from Parkinsonfonden, SRA Multipark, the Medical Faculty of Lund University, the Southern Swedish Health Care Region, and the \u00c5hlens Foundation. Per Odin has no relevant employment, or other financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data supporting the findings of this study, where not sourced from published material, are available within the article and its supplementary information.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: all authors. Acquisition, analysis, or interpretation of data: AS, SK, AK. Drafting of the manuscript: AS. Critical revision of the manuscript for important intellectual content: all authors. Administrative, technical, or material support: AS, SK, AK. Review and approval of final version: all authors.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}